natgillin/translations-raw huggingface dataset:
Служителите на Съвместното предприятие ИИЛ са временно наети и назначени по договор служители и имат срочни договори, които могат да се подновяват еднократно или общо за максимален срок от седем години.
The members of the staff of the IMI Joint Undertaking shall be temporary agents and contract agents and shall have fixed term contracts extendable once up to a maximum total period of seven years.
Members of the IMI Joint Undertaking staff may be subject to different forms of contract.
Members of the IMI Joint Undertaking staff may be subject to different forms of contract.
A flexible approach should allow a degree of freedom in the choice of contracts.
A flexible approach should allow a degree of freedom in the choice of contracts.
Приложение, член 17, параграф 5, буква а)
Annex, Article 17, paragraph 5, point (a)
а) микро, малки и средни предприятия по смисъла на Препоръка 2003/361/ЕО на Комисията, в съответствие със специфичните цели, предвидени за тях в Седмата рамкова програма;
(a) micro, small and medium-sized enterprises within the meaning of Commission Recommendation 2003/361/EC , in accordance with the specific objectives set for them by the Seventh Framework Programme;
Приложение, член 21, параграф 1
Annex, Article 21, paragraph 1
Всеки член на Съвместното предприятие ИИЛ може да внася предложения в Съвета за изменение на настоящия Устав.
Any Member of the IMI Joint Undertaking may make a proposal to the Board for the amendment of these Statutes.
Не касае българската версия
Does not affect English version
Does not affect English version.
Does not affect English version.
Приложение, член 21, параграф 2
Annex, Article 21, paragraph 2
Измененията в Устава се одобряват от Съвета.
Amendment to these Statutes shall be approved by the Board.
Ако изменението засяга цялостните принципи и цели на настоящия Устав, по-специално изменение на член 1, първо тире от член 5, параграф 2, буква в), член 8, параграф 3 и член 21, е необходимо и одобрението на Съвета по предложение на Комисията.
If such amendment affects the overall principals and objectives of these Statutes, in particular any amendment to Article 1, first indent of Article 5(2)(c), Article 8(3) and Article 21 shall be subject to approval by the Council based on a proposal by the Commission.
Ако изменението засяга цялостните принципи и цели на настоящия Устав, по-специално изменение на член 1, първо тире от член 5, параграф 2, буква в), член 8, параграф 3 и член 21, е необходимо и одобрението на Съвета по предложение на Комисията и след консултация с Европейския парламент.
If such amendment affects the overall principles and objectives of these Statutes, in particular any amendment to Article 1, the first indent of Article 5(2)(c), Article 8(3) and Article 21 shall be subject to approval by the Council based on a proposal by the Commission, and after consultation of the European Parliament.
The European Parliament needs to be consulted on any important changes to the JU's statutes.
The European Parliament needs to be consulted on any important changes to the JU's statutes.
Приложение, член 22, параграф 3, буква а)
Annex, Article 22, paragraph 3, point (a)
а) Всеки участващ в проект остава притежател на интелектуалната собственост, която внася в проекта, като също така остава притежател на интелектуалната собственост, която създава в рамките на проекта, освен ако няма друга договореност между участниците в проекта.
(a) Each participant in a project shall remain the owner of the intellectual property that it introduces into a project, and shall remain the owner of the intellectual property that it generates in a project unless otherwise mutually agreed by the participants in a project.
Сроковете и условията за права на достъп и лицензиране по отношение на интелектуалната собственост, предоставена или създадена от участниците в рамките на даден проект, се определят в споразумението за безвъзмездна помощ и договора по проекта.
The terms and conditions of access rights and licenses with regard to the intellectual property introduced into or generated by participants in a project, shall be defined in the Grant Agreement and the Project Agreement of the project concerned.
Участниците в проекта определят всички произтичащи от проектите случаи на съвместно притежаване на интелектуална собственост.
Project participants should establish any cases of co-ownership of intellectual property arising from projects.
As the IMI undertaking is a joint one, provision should be made for establishing co-ownership of intellectual property in cases where several participants achieve results determined by the various stakeholders.
As the IMI undertaking is a joint one, provision should be made for establishing co-ownership of intellectual property in cases where several participants achieve results determined by the various stakeholders.
Приложение, член 23 а (нов)
Annex, Article 23 a (new)
Споразумение за приемане
Host Agreement
Сключва се споразумение за приемане между Съвместното предприятие ИИЛ и Белгия.
A host agreement shall be concluded between the IMI Joint Undertaking and Belgium .
For the sake of consistency, the traditional host agreement clause should also be included in the statutes.
For the sake of consistency, the traditional host agreement clause should also be included in the statutes.
See also Amendment 6.
See also Amendment 6.
Research and innovation contribute directly to the prosperity and wellbeing of individuals and society.
Research and innovation contribute directly to the prosperity and wellbeing of individuals and society.
The main aim of technological research and development policy is to turn the European Union into a leading knowledge economy.
The main aim of technological research and development policy is to turn the European Union into a leading knowledge economy.
The European Union must make it possible to achieve the greatest possible cooperation at various levels, coordinate European and national policies more effectively, strengthen structural capacity and links between research teams and, finally, enhance the mobility of researchers and ideas.
The European Union must make it possible to achieve the greatest possible cooperation at various levels, coordinate European and national policies more effectively, strengthen structural capacity and links between research teams and, finally, enhance the mobility of researchers and ideas.
Joint technological initiatives (JTIs) are instruments defined in the specific programme 'Cooperation' of the Seventh Framework Programme.
Joint technological initiatives (JTIs) are instruments defined in the specific programme 'Cooperation' of the Seventh Framework Programme.
The JTI are the result of the work accomplished by the European technological platforms (ETP) launched under the Sixth Framework Programme to bring together public and private stakeholders to set up and implement joint research programmes in the field of industrial research.
The JTI are the result of the work accomplished by the European technological platforms (ETP) launched under the Sixth Framework Programme to bring together public and private stakeholders to set up and implement joint research programmes in the field of industrial research.
In a small number of cases, ETPs have achieved such an ambitious scale and scope that they considerable amounts of public and private investment will have to be mobilised in order to implement their research programmes.
In a small number of cases, ETPs have achieved such an ambitious scale and scope that they considerable amounts of public and private investment will have to be mobilised in order to implement their research programmes.
In contrast to the traditional approach, which involved providing projects with public funding on a case-by-case basis, JTIs are designed for large-scale research programme having joint strategic research objectives.
In contrast to the traditional approach, which involved providing projects with public funding on a case-by-case basis, JTIs are designed for large-scale research programme having joint strategic research objectives.
This new approach is designed to generate critical mass in terms of European research and innovation by consolidating the activities of the European scientific community in the main strategic areas.
This new approach is designed to generate critical mass in terms of European research and innovation by consolidating the activities of the European scientific community in the main strategic areas.
It will harmonise the funding of projects to ensure that research results can be put to use more swiftly.
It will harmonise the funding of projects to ensure that research results can be put to use more swiftly.
As one of these JTIs, the innovative medicines initiative (IMI) will finance pan-European public/private partnerships in the field of biomedical research.
As one of these JTIs, the innovative medicines initiative (IMI) will finance pan-European public/private partnerships in the field of biomedical research.
Although the EU is a world leader in many technologies, it needs to address an increasing number of challenges not only from its traditional competitors, but also from the emerging economies.
Although the EU is a world leader in many technologies, it needs to address an increasing number of challenges not only from its traditional competitors, but also from the emerging economies.
The joint programmes can obtain results which the Member States could not achieve by acting alone.
The joint programmes can obtain results which the Member States could not achieve by acting alone.
The emerging strength of the Indian and Chinese economies in the area of high-value-added technology is inducing the European Union to enhance its potential with regard to innovation, research and technology.
The emerging strength of the Indian and Chinese economies in the area of high-value-added technology is inducing the European Union to enhance its potential with regard to innovation, research and technology.
Innovation is one of the keys to the future success of the revised Lisbon Strategy for growth and employment.
Innovation is one of the keys to the future success of the revised Lisbon Strategy for growth and employment.
The EU seems, however, to be a victim of the paradoxical failings which prevent it from exploiting its potential to the full: an inability to convert the fruits of innovation into new products, patents and jobs; a large number of innovative small and medium-sized enterprises (SMEs) which are finding it difficult to grow and succeed at world level.
The EU seems, however, to be a victim of the paradoxical failings which prevent it from exploiting its potential to the full: an inability to convert the fruits of innovation into new products, patents and jobs; a large number of innovative small and medium-sized enterprises (SMEs) which are finding it difficult to grow and succeed at world level.
More particularly, the productivity of pharmaceutical research and development has been declining for three decades, although financial investment has been steadily increasing.
More particularly, the productivity of pharmaceutical research and development has been declining for three decades, although financial investment has been steadily increasing.
In 25 years, the amount of expenditure on research and development per pharmaceutical product placed on the market rose from € 54 million to € 880 million, equivalent to an annual increase of 11.8%.
In 25 years, the amount of expenditure on research and development per pharmaceutical product placed on the market rose from € 54 million to € 880 million, equivalent to an annual increase of 11.8%.
At the same time, there has been a significant drop in the duration of new drugs' effective profitability.
At the same time, there has been a significant drop in the duration of new drugs' effective profitability.
The average duration of the clinical development process has risen from 2.5 years in the 1960s to 6.5 years in the 1990s.
The average duration of the clinical development process has risen from 2.5 years in the 1960s to 6.5 years in the 1990s.
As an additional problem, there has been a rise in the failure rate of various stages of the testing process for new molecules.
As an additional problem, there has been a rise in the failure rate of various stages of the testing process for new molecules.
An increasing number of compounds is having to be tested to find one which would could be placed on the market.
An increasing number of compounds is having to be tested to find one which would could be placed on the market.
The Seventh Framework Programme for research, which covers the period from 2007-2013, offers the EU an opportunity to bring its research policy into line with its economic and social ambitions by consolidating the European Research Area (ERA).
The Seventh Framework Programme for research, which covers the period from 2007-2013, offers the EU an opportunity to bring its research policy into line with its economic and social ambitions by consolidating the European Research Area (ERA).
To achieve that objective, the Commission wishes to increase the EU's annual research budget and thereby stimulate greater national and private investment.
To achieve that objective, the Commission wishes to increase the EU's annual research budget and thereby stimulate greater national and private investment.
The implementation of the Seventh Framework Programme must also meet the research and knowledge requirements of industry and of European policy objectives in general.
The implementation of the Seventh Framework Programme must also meet the research and knowledge requirements of industry and of European policy objectives in general.
The Commission, the Member States and industry have decided to join forces by investing together in strategic research programmes.
The Commission, the Member States and industry have decided to join forces by investing together in strategic research programmes.
The Commission has proposed four joint technological initiatives.
The Commission has proposed four joint technological initiatives.
These JTIs will enable industry, the Member States and the Commission to pool their resources in the context of targeted research programmes.
These JTIs will enable industry, the Member States and the Commission to pool their resources in the context of targeted research programmes.
3) A new joint approach
3) A new joint approach
The IMI is a unique initiative jointly implemented by the Commission and the EFPIA (European Federation for Pharmaceutical Industries and Associations).
The IMI is a unique initiative jointly implemented by the Commission and the EFPIA (European Federation for Pharmaceutical Industries and Associations).
It will bring together public authorities, patients, universities, hospitals and representatives of the pharmaceutical industry to enable important progress to be made and address the complex issues involved in pre-competitive research and development.
It will bring together public authorities, patients, universities, hospitals and representatives of the pharmaceutical industry to enable important progress to be made and address the complex issues involved in pre-competitive research and development.
The IMI JU will have a total budget of EUR 2 billion for the period 2008-2013.
The IMI JU will have a total budget of EUR 2 billion for the period 2008-2013.
The Commission has allocated EUR 1 billion to the IMI JU under the Seventh Framework Programme.
The Commission has allocated EUR 1 billion to the IMI JU under the Seventh Framework Programme.
The Community's contribution will be paid in full to SMEs and universities to fund research which could be used by the pharmaceutical industry.
The Community's contribution will be paid in full to SMEs and universities to fund research which could be used by the pharmaceutical industry.
The big pharmaceutical companies will make an equivalent contribution and ensure the involvement of these SMEs and universities.
The big pharmaceutical companies will make an equivalent contribution and ensure the involvement of these SMEs and universities.
The IMI JU will, consequently, help boost private investment in R&D, improve knowledge transfer between universities and firms, and increase the participation of small businesses in the European research sector.
The IMI JU will, consequently, help boost private investment in R&D, improve knowledge transfer between universities and firms, and increase the participation of small businesses in the European research sector.
4) Appreciable benefits
4) Appreciable benefits
The innovative medicines initiative will aim to support the development of new knowledge, new tools and new methods in order to ensure more appropriate and safer medicines reach the market more rapidly.
The innovative medicines initiative will aim to support the development of new knowledge, new tools and new methods in order to ensure more appropriate and safer medicines reach the market more rapidly.
It will lead to better care for patients, particularly those suffering from cancer or cerebral, inflammatory, metabolic or infectious diseases.
It will lead to better care for patients, particularly those suffering from cancer or cerebral, inflammatory, metabolic or infectious diseases.
The purpose of the IMI JU is not to produce specific treatments but to identify bottlenecks in the R&D process, including pharmacovigilance, drug efficacy, knowledge management, education and training.
The purpose of the IMI JU is not to produce specific treatments but to identify bottlenecks in the R&D process, including pharmacovigilance, drug efficacy, knowledge management, education and training.
Progress in these four areas will make it possible to improve research with a view to discovering, and speeding up the development of, better medicines, particularly for the treatment of 'neglected diseases'.
Progress in these four areas will make it possible to improve research with a view to discovering, and speeding up the development of, better medicines, particularly for the treatment of 'neglected diseases'.
The collective approach developed by the IMI will reduce the risks involved for small firms and help them to develop products more swiftly by providing them with access to a common infrastructure, resources and equipment.
The collective approach developed by the IMI will reduce the risks involved for small firms and help them to develop products more swiftly by providing them with access to a common infrastructure, resources and equipment.
5) How the system will work
5) How the system will work
The IMI will involve a non-profit joint undertaking pursuant to Article 171 of the Treaty.
The IMI will involve a non-profit joint undertaking pursuant to Article 171 of the Treaty.
This joint undertaking will be supported by an executive office jointly funded and managed by the Commission and the EFPIA.
This joint undertaking will be supported by an executive office jointly funded and managed by the Commission and the EFPIA.
The latter will publish calls for research proposals.
The latter will publish calls for research proposals.
Groups of partners (universities, SMEs, bio-pharmaceutical companies, public authorities, patients) will form a public-private partnership to propose research initiatives.
Groups of partners (universities, SMEs, bio-pharmaceutical companies, public authorities, patients) will form a public-private partnership to propose research initiatives.
A public-private partnership shall include at least one university and/or SME, and one EFPIA member company.
A public-private partnership shall include at least one university and/or SME, and one EFPIA member company.
The Commission and the EFPIA have together drawn up a strategic research agenda for the IMI.
The Commission and the EFPIA have together drawn up a strategic research agenda for the IMI.
This document contains recommendations concerning the main bottlenecks.
This document contains recommendations concerning the main bottlenecks.
Europe needs a new approach to research in areas which offer promising prospects for our competitiveness and well-being.
Europe needs a new approach to research in areas which offer promising prospects for our competitiveness and well-being.
The proposals show that the Commission must now adopt a fresh approach to addressing Europe's requirements in that field.
The proposals show that the Commission must now adopt a fresh approach to addressing Europe's requirements in that field.
These public-private partnerships offer a new and promising alternative for pharmaceutical research, but also for all other areas of research activities.
These public-private partnerships offer a new and promising alternative for pharmaceutical research, but also for all other areas of research activities.
The rapporteur is pleased that approaches of this kind are being implemented.
The rapporteur is pleased that approaches of this kind are being implemented.
Some changes are proposed to the general framework laid down by the Commission proposal in order to clarify certain points.
Some changes are proposed to the general framework laid down by the Commission proposal in order to clarify certain points.
The distribution of intellectual property rights should be decided within the IMI JU, which will determine how any potential co-ownership issues should be resolved.
The distribution of intellectual property rights should be decided within the IMI JU, which will determine how any potential co-ownership issues should be resolved.
The interests of SMEs must not be sacrificed to those of other, bigger sections of the industry.
The interests of SMEs must not be sacrificed to those of other, bigger sections of the industry.
It is an essential pre-requisite, therefore, for the needs of SMEs to be taken more fully into account and for support measures to be taken to reduce any additional administrative burdens which might be imposed on them.
It is an essential pre-requisite, therefore, for the needs of SMEs to be taken more fully into account and for support measures to be taken to reduce any additional administrative burdens which might be imposed on them.
on the proposal for a Council regulation setting up the Innovative Medicines Initiative Joint Undertaking
on the proposal for a Council regulation setting up the Innovative Medicines Initiative Joint Undertaking
Joint Technology Initiatives (JTIs) are introduced in the Seventh Framework Programme
Joint Technology Initiatives (JTIs) are introduced in the Seventh Framework Programme
OJ L 412, 30.12.2006, p.
OJ L 412, 30.12.2006, p.
1 (FP7) as a new way of realising public-private partnerships in research at European level.
1 (FP7) as a new way of realising public-private partnerships in research at European level.
JTIs arise primarily from the work of European Technology Platforms (ETPs).
JTIs arise primarily from the work of European Technology Platforms (ETPs).
In a small number of cases, ETPs have reached such an ambitious scale and scope that they will require the mobilisation of considerable public and private investments as well as substantial research resources to implement important elements of their Strategic Research Agendas.
In a small number of cases, ETPs have reached such an ambitious scale and scope that they will require the mobilisation of considerable public and private investments as well as substantial research resources to implement important elements of their Strategic Research Agendas.
JTIs are proposed as means of meeting the needs of this small number of ETPs.
JTIs are proposed as means of meeting the needs of this small number of ETPs.
In the Cooperation Specific Programme
In the Cooperation Specific Programme
OJ L 400, 30.12.2006, p.
OJ L 400, 30.12.2006, p.
66-241. six areas are identified where a JTI could have particular relevance: hydrogen and fuel cells, aeronautics and air transport, innovative medicines, embedded computing systems, nanoelectronics and GMES (global monitoring for environment and security).
66-241. six areas are identified where a JTI could have particular relevance: hydrogen and fuel cells, aeronautics and air transport, innovative medicines, embedded computing systems, nanoelectronics and GMES (global monitoring for environment and security).